newsfilter
← Earnings
Earnings Releases·

Acumen Pharmaceuticals — Third Quarter 2026 Earnings Summary

Acumen Pharmaceuticals reported a net loss of $25.4 million for the third quarter of 2026, with cash, cash equivalents, and marketable securities totaling $78.6 million as of September 30, 2026. The company expects to announce topline results from its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in November 2026. Additionally, Acumen targets a mid-2027 Investigational New Drug filing for a lead candidate within its Enhanced Brain Delivery program. Research and development expenses for the quarter decreased to $21.1 million, primarily due to reduced manufacturing and clinical trial costs.

Company
ACUMEN PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology